Atria Investments Inc Invests $53,000 in uniQure (NASDAQ:QURE)

Atria Investments Inc acquired a new position in shares of uniQure (NASDAQ:QURE) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 10,844 shares of the biotechnology company’s stock, valued at approximately $53,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its stake in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares during the period. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. Total Clarity Wealth Management Inc. acquired a new stake in shares of uniQure during the second quarter worth $74,000. SG Americas Securities LLC purchased a new stake in shares of uniQure in the second quarter valued at $79,000. Finally, Ballentine Partners LLC acquired a new position in uniQure in the third quarter valued at $116,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

QURE has been the topic of a number of research analyst reports. The Goldman Sachs Group decreased their price target on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Royal Bank of Canada decreased their target price on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price target on shares of uniQure in a research report on Wednesday, November 6th. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Thursday, October 17th. Finally, Raymond James reissued an “outperform” rating and set a $20.00 price objective on shares of uniQure in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $17.00.

uniQure Trading Down 1.0 %

QURE opened at $5.78 on Monday. The firm has a market capitalization of $281.72 million, a P/E ratio of -1.17 and a beta of 0.90. The firm’s 50 day moving average is $5.93 and its 200-day moving average is $5.95. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Analysts expect that uniQure will post -3.81 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.